Cargando…

Docosahexaenoic Acid Serving As Sensitizing Agents And Gefitinib Resistance Revertants In EGFR Targeting Treatment

OBJECTIVE: Due to the resistance of cancer cells, chemotherapy has been severely restricted. Docosahexaenoic acid (DHA) has been broadly identified as the chemo-sensitizing agent and revertant of multidrug resistance owing to its pleiotropic characteristics; however, it has not been well interpreted...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Xuansheng, Ge, Lei, Yan, Aiwen, Ding, Yuyin, Tao, Junye, Liu, Qianqian, Qiao, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6897069/ https://www.ncbi.nlm.nih.gov/pubmed/31819534 http://dx.doi.org/10.2147/OTT.S225918

Ejemplares similares

Metformin revert insulin‐induced oxaliplatin resistance by activating mitochondrial apoptosis pathway in human colon cancer HCT116 cells
por: Liu, Chao, et al.
Publicado: (2020)

1,25-dihydroxyvitamin D3 signaling-induced decreases in IRX4 inhibits NANOG-mediated cancer stem-like properties and gefitinib resistance in NSCLC cells
por: Jia, Zhirong, et al.
Publicado: (2020)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Docosahexaenoic Acid Reverted the All-trans Retinoic Acid-Induced Cellular Proliferation of T24 Bladder Cancer Cell Line
por: Costantini, Lara, et al.
Publicado: (2020)

SFI Enhances Therapeutic Efficiency of Gefitinib: An Insight into Reversal of Resistance to Targeted Therapy in Non-small Cell Lung Cancer Cells
por: Pan, Zhenzhen, et al.
Publicado: (2020)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations
por: Xin, Shuang, et al.
Publicado: (2015)

ω-3 Long Chain Polyunsaturated Fatty Acids as Sensitizing Agents and Multidrug Resistance Revertants in Cancer Therapy
por: Corsetto, Paola Antonia, et al.
Publicado: (2017)

Comparison of first-generation EGFR-TKIs (gefitinib, erlotinib, and icotinib) as adjuvant therapy in resected NSCLC patients with sensitive EGFR mutations
por: He, Qihua, et al.
Publicado: (2021)

LPCAT1 promotes gefitinib resistance via upregulation of the EGFR/PI3K/AKT signaling pathway in lung adenocarcinoma
por: Ding, Jianghua, et al.
Publicado: (2022)

AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations
por: Zhao, Ren, et al.
Publicado: (2016)

Gefitinib sensitization of cisplatin-resistant wild-type EGFR non-small cell lung cancer cells
por: Li, Amin, et al.
Publicado: (2020)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib
por: Yuan, Ying, et al.
Publicado: (2012)

TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription
por: Yuan, Weiwei, et al.
Publicado: (2019)

Enhanced Production of Docosahexaenoic Acid in Mammalian Cells
por: Zhu, Guiming, et al.
Publicado: (2014)

Gefitinib upregulates death receptor 5 expression to mediate rmhTRAIL-induced apoptosis in Gefitinib-sensitive NSCLC cell line
por: Yan, Dong, et al.
Publicado: (2015)

Will It Revert to Pageantry and Burlesque?
Publicado: (1920)

Circulating Docosahexaenoic Acid Levels Are Associated with Fetal Insulin Sensitivity
por: Zhao, Jin-Ping, et al.
Publicado: (2014)

Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction
por: Wang, Wen-Ping, et al.
Publicado: (2012)

Role of Endocytosis Proteins in Gefitinib-Mediated EGFR Internalisation in Glioma Cells
por: Cruz Da Silva, Elisabete, et al.
Publicado: (2021)

Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis
por: Saito, Yu, et al.
Publicado: (2018)

Phenformin alone or combined with gefitinib inhibits bladder cancer via AMPK and EGFR pathways
por: Huang, Yanjun, et al.
Publicado: (2018)

Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy
por: Li, Xiao-Qiu, et al.
Publicado: (2016)

Pharmacokinetic interaction between epirubicin and the multidrug resistance reverting agent D-verapamil.
por: Scheithauer, W., et al.
Publicado: (1993)

Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis
por: Zou, Bin, et al.
Publicado: (2018)

Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET
por: Oh, Ha-Na, et al.
Publicado: (2020)

Interferon-α reduces the gefitinib sensitivity of human non-small cell lung cancer
por: Pan, Chi, et al.
Publicado: (2016)

Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non–Small-Cell Lung Cancer With Mutated EGFR
por: Miyauchi, Eisaku, et al.
Publicado: (2022)

Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII
por: Pedersen, M W, et al.
Publicado: (2005)

The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations
por: Song, Ruiqiang, et al.
Publicado: (2022)

Revertant Mosaicism in Epidermolysis Bullosa
por: Meyer-Mueller, Cameron, et al.
Publicado: (2022)

Claudin1 decrease induced by 1,25-dihydroxy-vitamin D3 potentiates gefitinib resistance therapy through inhibiting AKT activation-mediated cancer stem-like properties in NSCLC cells
por: Jia, Zhirong, et al.
Publicado: (2022)

Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib
por: WANG, XINZHAO, et al.
Publicado: (2015)

Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive EGFR mutations
por: Jiang, Xuhong, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China
por: Shu, Yamin, et al.
Publicado: (2021)

A "late-but-fitter revertant cell" explains the high frequency of revertant mosaicism in epidermolysis bullosa
por: van den Akker, Peter C., et al.
Publicado: (2018)

Exosome-mediated microRNA signaling from breast cancer cells is altered by the anti-angiogenesis agent docosahexaenoic acid (DHA)
por: Hannafon, Bethany N., et al.
Publicado: (2015)

Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression
por: Pan, Zhenzhen, et al.
Publicado: (2022)

MYCN and PRC1 cooperatively repress docosahexaenoic acid synthesis in neuroblastoma via ELOVL2
por: Ding, Yi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_88c96amoccmtkj9svedaangtpo